Society for Cardiovascular Angiography and Interventions (SCAI) 2022 Scientific Sessions

Among patients undergoing femoropopliteal artery revascularization, mortality risk was not affected regardless of whether they were treated with drug-coated devices (DCDs) or non–drug-coated devices (NDCDs), according to updated results of the SAFE-PAD* study presented at SCAI 2022.

One year after undergoing percutaneous coronary intervention (PCI), high-risk patients on clopidogrel monotherapy have a reduced risk of multiple cardiovascular (CV) outcomes compared with those on aspirin monotherapy, according to a study presented at SCAI 2022.

In the Disrupt PAD III trial, superior primary patency (PP) was achieved at 1 year with intravascular lithotripsy (IVL) plus a drug-coated balloon (DCB) compared with percutaneous transluminal angioplasty (PTA) + DCB, confirming the consistent safety and efficacy of IVL to facilitate a durable approach for individuals with heavily calcified femoropopliteal arteries largely without stent requirement.

In an expanded analysis presented at SCAI 2022, recipients of the Harmony transcatheter pulmonary valve (TPV) continued to demonstrate favourable clinical and haemodynamic outcomes, confirming previous results and showing continued device success across studies and valve types at 1 year and beyond.